Elite Pharmaceuticals Files Q3 2025 10-Q
Ticker: ELTP · Form: 10-Q · Filed: Feb 13, 2025 · CIK: 1053369
| Field | Detail |
|---|---|
| Company | Elite Pharmaceuticals INC /NV/ (ELTP) |
| Form Type | 10-Q |
| Filed Date | Feb 13, 2025 |
| Risk Level | medium |
| Pages | 14 |
| Reading Time | 17 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, quarterly-report, pharmaceuticals
Related Tickers: ELTP
TL;DR
**Elite Pharma (ELTP) dropped its Q3 2025 10-Q. Check financials.**
AI Summary
Elite Pharmaceuticals Inc. reported its third quarter results for the fiscal year ending March 31, 2025. The company's filing covers the period from October 1, 2024, to December 31, 2024. Key financial data and business segment information are detailed within this 10-Q filing.
Why It Matters
This filing provides investors with the latest financial performance and operational updates for Elite Pharmaceuticals, crucial for understanding the company's current standing and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Elite Pharmaceuticals faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- Q3 2025 — Fiscal Quarter (Reporting period for the 10-Q)
- 2024-12-31 — Period End Date (The end date of the financial reporting period)
- 2025-02-13 — Filing Date (The date the 10-Q was officially submitted to the SEC)
Key Players & Entities
- Elite Pharmaceuticals Inc. (company) — Filer of the 10-Q
- 2024-12-31 (date) — End of the reporting period
- 2025-02-13 (date) — Filing date
- 2024-10-01 (date) — Start of the reporting period
FAQ
What is the reporting period covered by this 10-Q filing?
This 10-Q filing covers the third quarter of the fiscal year ending March 31, 2025, specifically from October 1, 2024, to December 31, 2024.
What is the company's Central Index Key (CIK)?
The company's Central Index Key (CIK) is 0001053369.
What is Elite Pharmaceuticals' fiscal year end?
Elite Pharmaceuticals' fiscal year ends on March 31.
What is the company's business address?
The company's business address is 165 Ludlow Avenue, Northvale, NJ 07647.
What SIC code is associated with Elite Pharmaceuticals?
Elite Pharmaceuticals is associated with SIC code 2834, which is for Pharmaceutical Preparations.
Filing Stats: 4,315 words · 17 min read · ~14 pages · Grade level 18.8 · Accepted 2025-02-13 16:05:31
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ELTP OTCQB Indicate by
Filing Documents
- form10-q.htm (10-Q) — 1626KB
- ex31-1.htm (EX-31.1) — 15KB
- ex31-2.htm (EX-31.2) — 15KB
- ex32-1.htm (EX-32.1) — 5KB
- ex32-2.htm (EX-32.2) — 7KB
- 0001493152-25-006427.txt ( ) — 8110KB
- eltp-20241231.xsd (EX-101.SCH) — 54KB
- eltp-20241231_cal.xml (EX-101.CAL) — 86KB
- eltp-20241231_def.xml (EX-101.DEF) — 199KB
- eltp-20241231_lab.xml (EX-101.LAB) — 464KB
- eltp-20241231_pre.xml (EX-101.PRE) — 367KB
- form10-q_htm.xml (XML) — 1485KB
SIGNATURES
SIGNATURES 17 i PART I - FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS ELITE PHARMACEUTICALS, INC. AND SUBSIDIARY CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) December 31, 2024 March 31, 2024 ASSETS Current assets: Cash $ 8,293,068 $ 7,106,262 Accounts receivable, net of allowance for expected credit losses of $ 220,000 and $ 236,000 respectively 18,454,012 19,453,301 Inventory 20,157,890 12,930,464 Prepaid expenses and other current assets 1,144,707 524,162 Total current assets 48,049,677 40,014,189 Property and equipment, net of accumulated depreciation of $ 16,738,308 and $ 15,906,853 respectively 9,863,527 10,175,293 Intangible assets 7,241,228 6,341,228 Finance lease - right-of-use asset 1,890,967 2,079,658 Operating lease - right-of-use asset 2,110,917 2,355,201 Deferred income tax asset 20,689,381 22,160,895 Other assets: Restricted cash - debt service for NJEDA bonds 449,216 432,832 Security deposits 461,551 94,240 Total other assets 910,767 527,072 Total assets $ 90,756,464 $ 83,653,536 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable $ 5,840,356 $ 2,714,306 Accrued expenses 3,719,013 5,301,747 Deferred revenue, current portion 8,889 13,333 Bonds payable, current portion, net of bond issuance costs 125,822 115,822 Loans payable, current portion 164,177 180,399 Related party loans payable (Note 7) 4,000,000 4,000,000 Lease obligation - finance lease, current portion 373,178 312,739 Lease obligation - operating lease, current portion 457,397 411,418 Total current liabilities 14,688,832 13,049,764 Long-term liabilities: Deferred revenue, net of current portion — 5,556 Bonds payable, net of current portion and bond issuance costs 783,836 913,203 Loans payable, net of current portion and loan costs 2,268,612 2,366,487 Lease obligation - finance lease, net of current portion 1,327,602 1,480,317